Corresponding Author: Anthony B. Daniels, MD, MSc, Division of Ocular Oncology and Pathology, Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, 2311 Pierce Ave, Ste 2252, Nashville, TN 37205 (email@example.com).
Published Online: January 21, 2021. doi:10.1001/jamaophthalmol.2020.4675
Conflict of Interest Disclosures: Dr Froehler has received grants from the National Institutes of Health, Genentech, Medtronic, Stryker, Microvention, and Penumbra and personal fees from Genentech, Medtronic, Stryker, Balt, Cerenovus, Viz.ai, and Corindus. Dr Daniels has received grants from the National Eye Institute and Research to Prevent Blindness Foundation during the conduct of the study and grants from Spectrum Pharmaceuticals and Alcon Research Institute outside the submitted work; and has a patent with Vanderbilt University Medical Center. No other disclosures were reported.
Funding/Support: This work was supported by grant K08 EY 027464 from the National Eye Institute (Dr Daniels), by a Research to Prevent Blindness Career Development Award (Dr Daniels), and by an unrestricted grant from Research to Prevent Blindness to the Vanderbilt Department of Ophthalmology and Visual Sciences.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the mother of the patient for granting permission to publish this information.
DH , Dunkel
IJ , Brodie
SE , Kim
JW , Gobin
YP . A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology
. 2008;115(8):1398-1404, 1404.e1. doi:10.1016/j.ophtha.2007.12.014PubMedGoogle ScholarCrossref
S , Friedman
DL , Daniels
AB . Alternative chemotherapeutic agents for the treatment of retinoblastoma using the intra-arterial and intravitreal routes: a path forward toward drug discovery. Int Ophthalmol Clin
. 2017;57(1):129-141. doi:10.1097/IIO.0000000000000154PubMedGoogle ScholarCrossref
AB , Froehler
MT , Nunnally
et al. Rabbit model of intra-arterial chemotherapy toxicity demonstrates retinopathy and vasculopathy related to drug and dose, not procedure or approach. Invest Ophthalmol Vis Sci
. 2019;60(4):954-964. doi:10.1167/iovs.18-25346PubMedGoogle ScholarCrossref
PR , Schremp
EA , Friedman
DL , Koyama
T , Froehler
MT , Daniels
AB . Adverse events, treatment burden, and outcomes of intravenous versus intra-arterial chemotherapy for retinoblastoma. Ophthalmol Retina
. Published online September 11, 2020. doi:10.1016/j.oret.2020.09.006PubMedGoogle Scholar